12:00 AM
 | 
Sep 15, 2014
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
Company Bank Analyst Coverage Opinion Wk chg 9/12cls
BioDelivery Sciences International Inc. (NASDAQ:BDSI) Summer Street Jim Molloy Price target Buy 11% $18.15
Molloy raised his target to $28 from $20 because of higher expectations for the market penetration of addiction drugs Bunavail buprenorphine/naloxone and BEMA Buprenorphine (EN3409) after a BioDelivery analyst day. Molloy said two addiction specialist presenters showed there is a "stark need" for treatments such as Bunavail with fewer side effects than Suboxone from Reckitt Benckiser Group plc (LSE:RB)....

Read the full 596 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >